Subscribe to receive this FREE daily commentary directly in your email
[widget id=”wordads_sidebar_widget-41″]
Technology Stocks Continue To Rule The Land: Monster Week In Review
The first week of 2018 was no disappointment with stock starting off precisely where they left off 2017. To know displeasure, only four of the top 25 stocks in the S&P 500 were lower: Intel ($INTC), AT&T (T), Verizon ($VZ), and Procter & Gamble ($PG). While Facebook ($FB), Alphabet ($GOOGL), and Amazon ($AMZN) were all up by over 5 percent.
Join our 2,630 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe
[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]
Technology Stocks
Technology stocks continue to lead the charge, with the “FANG’s” consisting of the top 3 performing stock in the S&P 500. But when we look deeper into the technology sector stocks, we can see it was the chip stocks, Micron ($MU), Nvidia ($NVDA), and Applied Materials ($AMAT) that were the leaders, with PayPal ($PYPL) also putting up a solid week.
Micron
Micron shares look like they may have finally turned for the better after reporting solid results back in December. We can see in the chart below the gap that we had written about a couple of weeks ago did indeed get filled, while the lows around $40 were successfully tested. With the stock also taking out the post-result highs, Micron appears well positioned to make a run towards $50.Â
If for some reason this stock doesn’t successfully make it back to $50, I would suspect that the market is trying to send us a message about its faith in Micron’s ability to consistently grow earnings and keep margins healthy. Continue to watch how this one trades this coming week.Â
Nvidia
Nvidia made a huge come back this past week, with shares nearly touching its all-time highs around $218. The stock failed two times this past week to move above $219, and that could be a problem for Nvidia. $219 is critical and the stock will need to break through that level or a I fear a re-test of the $185 level.Â
IBMÂ
IBM had a solid week with shares of the stock climbing by nearly 6 percent. Shares are nearing a big breakout at $162.65. If shares can keep their forward momentum, I can see a rally taking it to downtrend line around $175. I don’t think IBM has much to offer above and beyond that price.Â
The company to this point has not solved its revenue issue, and legacy revenue is still the dominant supplier of that income.Â
IBM Annual Revenue Estimates data by YCharts
Healthcare Conference
This week kicks off the JP Morgan Healthcare conference, and that means there should be plenty of news coming out biotech stock group. Biogen ($BIIB) was the best performing name in the group, with its shares jumping by nearly 8 percent to start the year.Â
Incyte
Incyte shares from a technical point look as though they may have bottomed. They finally appear back to where they started 2017 and filled the gap.Â
That is going to be it for today, back tomorrow with a look at the week ahead.Â
On-Demand Content
Apple iPhone Shipment Maybe Better Than Feared
Why Biotech May Outperform In 2018Â
Sign-up for our premium content on Seeking Alpha Market Place – “Reading The Markets” and a get Two Week Free Trial Period
Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments.Â
We will respond to questions in short order and will respond to questions with full-post or video segment, just not one or two-word answers.Â
Now JUST $25 Per Month
An Intelligent Way Of Looking At Tesla’s Results
3 Biotech Names To Start The Year
Disney- The Market Finally Get’s It
Why The FANG’s Could Lead In 2018
Tech Wreck V12.4.17 – More Room Too Fall
Why The S&P500 Could Melt-Up Into Year End
Free Articles Written By Mike:
Nvidia’s Stock Faces Its Moment of Truth
Why AMD May Rise 17% Higher On Intel’s Woes
Why These 3 Oil Stocks Will Outperform
Why NXP Shareholders Will Prosper Without a Qualcomm Deal
Netflix Breakout Seen Boosting Stock By 17%
We offer daily market commentaries sent directly to your inbox or follow us on Twitter.
Join our 2,630 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe
-OR-
[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]
Michael Kramer and the Clients of Mott Capital own shares of VZ
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
© 2017 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Tags: #xlk #technology #stocks #nvidia #micron #incyte #ibm
Subscribe to receive this FREE daily commentary directly in your email
This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.